Positive Ph III data may mark start of European push in ADHD for Shire
This article was originally published in Scrip
Executive Summary
Shire has reported positive top-line data from a European Phase III study of its amphetamine-based attention deficit hyperactivity disorder treatment Lisdexamfetamine dimesylate (LDX) in children.